NCT02727933View on ClinicalTrials.gov

Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea

CompletedOBSERVATIONAL
Enrollment

1,941

Participants

Timeline

Start Date

November 3, 2015

Primary Completion Date

July 5, 2020

Study Completion Date

July 5, 2020

Conditions
Hepatitis C
Trial Locations (1)

Unknown

Local Institution, Seoul

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02727933 - Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea | Biotech Hunter | Biotech Hunter